Cited 31 times in
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김아영 | - |
dc.contributor.author | 김지홍 | - |
dc.contributor.author | 신재일 | - |
dc.contributor.author | 이성수 | - |
dc.contributor.author | 우원기 | - |
dc.date.accessioned | 2022-07-08T03:26:43Z | - |
dc.date.available | 2022-07-08T03:26:43Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1201-9712 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188856 | - |
dc.description.abstract | Objectives: To meta-analyse the clinical manifestations, diagnosis, treatment, and mortality of vaccine-induced immune thrombotic thrombocytopenia (VITT) after adenoviral vector vaccination. Methods: Eighteen studies of VITT after ChAdOx1 nCoV-19 or Ad26.COV2.S vaccine administration were reviewed from PubMed, Scopus, Embase, and Web of Science. The meta-analysis estimated the summary effects and between-study heterogeneity regarding the incidence, manifestations, sites of thrombosis, diagnostic findings, and clinical outcomes. Results: The incidence of total venous thrombosis after ChAdOx1 nCoV-19 vaccination was 28 (95% CI 12-52, I2=100%) per 100,000 doses administered. Of 664 patients included in the quantitative analysis (10 studies), the mean age of patients with VITT was 45.6 years (95% CI 43.8-47.4, I2=57%), with a female predominance (70%). Cerebral venous thrombosis (CVT), deep vein thrombosis (DVT)/pulmonary thromboembolism (PE), and splanchnic vein thrombosis occurred in 54%, 36%, and 19% of patients with VITT, respectively. The pooled incidence rate of CVT after ChAdOx1 nCoV-19 vaccination (23 per 100,000 person-years) was higher than that reported in the pre-pandemic general population (0.9 per 100,000 person-years). Intracranial haemorrhage and extracranial thrombosis accompanied 47% and 33% of all patients with CVT, respectively. The antiplatelet factor 4 antibody positivity rate was 91% (95% CI 88-94, I2=0%) and the overall mortality was 32% (95% CI 24-41, I2=69%), and no significant difference was observed between heparin- and non-heparin-based anticoagulation treatments (risk ratio 0.84, 95% CI 0.47-1.50, I2=0%). Conclusions: Patients with VITT after SARS-CoV-2 vaccination most frequently presented with CVT following DVT/PE and splanchnic vein thrombosis, and about one-third of patients had a fatal outcome. This meta-analysis should provide a better understanding of VITT and assist clinicians in identifying VITT early to improve outcomes and optimise management. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Ad26COVS1 | - |
dc.subject.MESH | COVID-19 Vaccines / adverse effects | - |
dc.subject.MESH | COVID-19* / prevention & control | - |
dc.subject.MESH | ChAdOx1 nCoV-19 | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Purpura, Thrombocytopenic, Idiopathic* / epidemiology | - |
dc.subject.MESH | Purpura, Thrombocytopenic, Idiopathic* / etiology | - |
dc.subject.MESH | SARS-CoV-2 | - |
dc.subject.MESH | Thrombocytopenia* / etiology | - |
dc.subject.MESH | Thrombosis* / epidemiology | - |
dc.subject.MESH | Thrombosis* / etiology | - |
dc.subject.MESH | Vaccines* | - |
dc.subject.MESH | Venous Thrombosis* / chemically induced | - |
dc.subject.MESH | Venous Thrombosis* / etiology | - |
dc.title | Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Ah Young Kim | - |
dc.contributor.googleauthor | Wongi Woo | - |
dc.contributor.googleauthor | Dong Keon Yon | - |
dc.contributor.googleauthor | Seung Won Lee | - |
dc.contributor.googleauthor | Jae Won Yang | - |
dc.contributor.googleauthor | Ji Hong Kim | - |
dc.contributor.googleauthor | Seoyeon Park | - |
dc.contributor.googleauthor | Ai Koyanagi | - |
dc.contributor.googleauthor | Min Seo Kim | - |
dc.contributor.googleauthor | Sungsoo Lee | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.contributor.googleauthor | Lee Smith | - |
dc.identifier.doi | 10.1016/j.ijid.2022.03.034 | - |
dc.contributor.localId | A04727 | - |
dc.contributor.localId | A01003 | - |
dc.contributor.localId | A02142 | - |
dc.contributor.localId | A02866 | - |
dc.relation.journalcode | J01125 | - |
dc.identifier.eissn | 1878-3511 | - |
dc.identifier.pmid | 35339716 | - |
dc.subject.keyword | COVID-19 vaccine | - |
dc.subject.keyword | adverse event | - |
dc.subject.keyword | cerebral venous thrombosis | - |
dc.subject.keyword | splanchnic vein thrombosis | - |
dc.subject.keyword | vaccine thrombosis | - |
dc.subject.keyword | vaccine-induced immune thrombotic thrombocytopenia. | - |
dc.contributor.alternativeName | Kim, Ah Young | - |
dc.contributor.affiliatedAuthor | 김아영 | - |
dc.contributor.affiliatedAuthor | 김지홍 | - |
dc.contributor.affiliatedAuthor | 신재일 | - |
dc.contributor.affiliatedAuthor | 이성수 | - |
dc.citation.volume | 119 | - |
dc.citation.startPage | 130 | - |
dc.citation.endPage | 139 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, Vol.119 : 130-139, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.